UGT2B7 is a UDP-glucuronosyltransferase that catalyzes phase II biotransformation through glucuronidation, conjugating lipophilic substrates with glucuronic acid to increase water solubility and facilitate urinary or biliary excretion 1. This enzyme is essential for eliminating and detoxifying drugs, xenobiotics, and endogenous compounds 2. UGT2B7 metabolizes diverse substrates including steroid hormones (androgens and estrogens) 1, retinoic acid affecting apoptosis and cellular differentiation 1, bile acids involved in lipid absorption 2, and arachidonic acid-derived eicosanoids 2. The enzyme also metabolizes pharmaceutical agents including morphine, AZT, losartan, and mycophenolate 1. UGT2B7 is primarily expressed in liver and steroid target tissues, localized to endoplasmic reticulum and nuclear membranes 2. The gene spans approximately 16 kb with six exons and contains regulatory elements including Oct-1, Pbx-1, and C/EBP binding sites 1. UGT2B7 expression is subject to post-transcriptional regulation by miR-485-5p 3 and influenced by pregnane X receptor signaling 4. Genetic polymorphisms in UGT2B7 associate with variable drug metabolism and clinical outcomes in epilepsy treatment 5. A GAAA-repeat expansion near the UGT2B7 promoter appears enriched in renal cell carcinoma 6.